Throughout the past two decades the efforts to improve treatment efficacy for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) have led to increased use of multimodality approaches combining surgery, radiotherapy (RT), and chemotherapy (CT). In fact, conventional RT was associated with unsatisfactory patients' outcomes, thereby a greater understanding of radiobiology led to the development of altered irradiation schedules, such as hyperfractionation (HF) and accelerated fractionation (AF), in the management of advanced HNSCC. Randomized controlled trials and meta-analyses demonstrated that for patients with locally advanced HNSCC, major improvements in loco-regional control and overall survival rates may be obtained by AF and HF with increased total radiation dose. CT represents an important component of multimodality treatment approach for locally advanced HNSCC. The combination of concurrent CT and RT (CCRT) provides a substantial and statistically significant improvement in survival and loco-regional control, as compared to RT alone. CCRT has been also shown to preserve healthy tissue in almost two thirds of patients, without affecting survival. However, despite hundreds of clinical trials in patients with advanced disease, there is no widespread consensus about patient selection for altered fractionation regimens, type of chemo-radiotherapy association, radiation/ chemotherapy dose schedule in LA-HNSCC. The state of the art of radiobiological models for tumor control and toxicity after CCRT will be presented together with methods of BED calculation. Model parameters will be introduced to be applicable to different chemotherapy schedules. The aim is to highlight the potential convenience of using radiobiology in the selection more effective treatment strategies. As secondary aim BED for combined CCRT with/without hyperthermia (HT) will be introduced to further stress the versatility of radiobiological concepts in predicting patient' outcome and improving the efficacy of treatment strategies.
Symposium: Proton therapy, from rationale to planning and delivery

SP-0370 Clinical rationale S.E. Combs 1 1 Klinikum Rechts der Isar, Department of Radiation Oncology, Munich, Germany
Particle therapy offers distinct physical properties leading to reduction of integral dose. For low-LET particles, biology is relatively comparable to photons, however, if this often cited sentence is correct in detail, is a matter of discussion. Albeit known heterogeneities and differences, altogether, the relative biological effectiveness (RBE) is postulated to be around 1.1. Proton therapy requires elaborate, large and expensive facilities, leading to a cost that is several times higher than advanced photon treatments. Treatment planning for particle therapy is delicate, special knowledge and training is necessary, and caution must be met at all steps. In spite of all these challenges, there is a strong rationale that the physical benefits of particle therapy convert into a clinical benefit for the patient. To date, however, no randomized trial has shown these benefits. For certain indications, the argument for proton therapy is evident, such as some skull base tumors, or pediatric patients, when timely proton treatment is available. Currently, with many centers worldwide, reserach foci are ongoing in different disease groups, as well as in terms of further pre-clinical assessment, to define the therapeutic window or proton therapy.
SP-0371
Treatment planning for proton therapy ñ a challenge for the whole team C. Vallhagen Dahlgren 1 1 Skandionkliniken, Skandionkliniken, Uppsala, Sweden
The first Scandinavian Proton Centre, Skandionkliniken, is planned to treat its first patient in June 2015; a facility owned by the seven regions with university hospitals. Patients will be referred to Skandionkliniken through these hospitals utilising "distributed competence" [1] . The patients will be prepared for treatment at their "home centre"; immobilisation, CT-scanning and treatment planning will be performed at the university hospital. All treatment plans will be reviewed at joint teleconference meetings [2] prior to the treatment start. The patient and any individual immobilisation device will be sent to Skandionkliniken for treatment. Skandionkliniken will be a "spot scanning only" facility.
